GlassScriptPhysician profile
Rohan Chawla
NPI 1437442183
$10,376.05
in general payments reported to CMS, 2019-2025
31 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2020: $432 · 2021: $975 · 2022: $1,637 · 2023: $2,245 · 2024: $1,622 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,840 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,840.08 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,308.06 | 2019-2025 | Enbrel, Evenity, Tavneos |
| Abbvie INC. | $1,831.06 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $980.96 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $968.27 | 2019-2025 | Cimzia, Bimzelx |
| Genzyme Corporation | $646.61 | 2019-2025 | |
| Pfizer INC. | $624.69 | 2019-2025 | |
| Lilly USA, LLC | $531.99 | 2019-2025 | Taltz |
| Novartis Pharmaceuticals Corporation | $462.08 | 2019-2025 | |
| Genentech USA, INC. | $239.17 | 2019-2024 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $234.94 | 2019-2025 | Orencia |
| Radius Health, INC. | $195.11 | 2020-2025 | Tymlos |
| Horizon Therapeutics Plc | $184.24 | 2019-2023 | Krystexxa |
| Celgene Corporation | $143.01 | 2019 | |
| Alexion Pharmaceuticals, INC. | $141.23 | 2022-2025 | Strensiq |
| Sobi, INC | $136.27 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $116.59 | 2021-2023 | Saphnelo |
| Scilex Pharmaceuticals INC. | $93.56 | 2024-2025 | |
| Sandoz INC. | $78.11 | 2023-2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.60 | 2023-2024 | Cyltezo |
| Fidia Pharma USA INC. | $63.04 | 2019-2024 | Hym/Hyn, Hymovis, Triluron |
| Glaxosmithkline, LLC. | $48.72 | 2023-2024 | Benlysta |
| Kiniksa Pharmaceuticals, LTD. | $47.09 | 2023 | Arcalyst |
| Mallinckrodt Enterprises LLC | $44.64 | 2019 | |
| Alvogen INC | $43.84 | 2024 | Teriparatide |
| Qiagen, LLC | $28.77 | 2022 | |
| Medexus Pharma, INC. | $23.59 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $19.92 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.52 | 2023 | Truxima |
| Kiniksa Pharmaceuticals International, Plc | $16.19 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $16.12 | 2020 | |
| Bioventus LLC | $15.06 | 2023 | L360 Thigh System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohan Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.